Sinopep-Allsino Biopharmaceutical Co. Ltd. A

SHG:688076 China Biotechnology
Market Cap
$1.38 Billion
CN¥10.14 Billion CNY
Market Cap Rank
#8203 Global
#1508 in China
Share Price
CN¥32.08
Change (1 day)
-1.75%
52-Week Range
CN¥31.06 - CN¥61.70
All Time High
CN¥90.43
About

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more

Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: 0.022x

Based on the latest financial reports, Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076) has a cash flow conversion efficiency ratio of 0.022x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥68.66 Million) by net assets (CN¥3.13 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

Sinopep-Allsino Biopharmaceutical Co. Ltd. A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sinopep-Allsino Biopharmaceutical Co. Ltd. A ranked by their cash flow conversion efficiency.

Annual Cash Flow Conversion Efficiency for Sinopep-Allsino Biopharmaceutical Co. Ltd. A (2013–2024)

The table below shows the annual cash flow conversion efficiency of Sinopep-Allsino Biopharmaceutical Co. Ltd. A from 2013 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥2.68 Billion CN¥400.12 Million 0.149x -6.75%
2023-12-31 CN¥2.19 Billion CN¥350.21 Million 0.160x +951.19%
2022-12-31 CN¥1.92 Billion CN¥29.29 Million 0.015x -84.77%
2021-12-31 CN¥1.81 Billion CN¥180.75 Million 0.100x -31.72%
2020-12-31 CN¥966.02 Million CN¥141.38 Million 0.146x +166.14%
2019-12-31 CN¥838.98 Million CN¥46.14 Million 0.055x -55.04%
2018-12-31 CN¥785.38 Million CN¥96.06 Million 0.122x +253.60%
2017-12-31 CN¥321.20 Million CN¥11.11 Million 0.035x +105.51%
2016-12-31 CN¥34.95 Million CN¥-21.95 Million -0.628x +59.12%
2015-12-31 CN¥73.32 Million CN¥-112.62 Million -1.536x +51.62%
2014-12-31 CN¥-21.47 Million CN¥68.18 Million -3.175x -126.79%
2013-12-31 CN¥3.69 Million CN¥43.67 Million 11.850x --